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Abstract: Malignant melanoma represents one of the most aggressive malignancies but outcome is highly variable with 
early tumor lesions having an excellent prognosis following resection. We review here the data on identification of genes 
involved in the progression of melanoma as a result of expression array studies, genomic profiling, and genetic models. 
We focus on the role of tumor suppressors involved in cell cycle function, DNA repair, and genome maintenance. High-
lighted are the roles of loss of p16 in promoting neoplasia in cooperation with deregulated MAPK signaling, and the role 
of loss of the RASSF1A protein in promoting chromosomal instability. The interactions between point mutation in growth 
signaling molecules and epigenetic changes in genes involved in DNA repair and cell division are discussed.  
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I. HETEROGENEITY IN MELANOMA: CLINICAL 
PRESENTATION AND OUTCOMES  
  Melanoma arises from malignant transformation of 
melanocytes and has an aggressive course once the tumor 
has spread beyond the superficial skin. However, like all 
tumor types there is considerable heterogeneity in outcome 
and molecular pathogenesis. Clinically distinct patterns of 
melanoma include acral lentiginous (AL) presenting in the 
distal extremities, and superficial spreading (SS), lentigo 
maligna, and nodular types. Almost all histologic and clini-
cal patterns of melanoma are increased in patients with a 
history of heavy sun exposure, particularly discrete serious 
sunburn episodes but other risk factors are poorly under-
stood. Mucosal and soft tissue presentations of melanoma 
while rare appear to have a distinct pathogenesis. There are 
also a variety of different histologic appearances in mela-
noma including the typical epithelioid forms, as well as des-
moplastic (spindle cell) and anaplastic variants. Approxi-
mately 5-10% of melanomas have a strong familial link, and 
the molecular defects in most of these cases involve cell cy-
cle regulators, particularly cyclin-dependent kinases (CDKs) 
and the CDK inhibitor p16 (CDKN2A) in their molecular 
pathogenesis [1-5].  
II. THERAPEUTIC OPTIONS FOR MELANOMA  
  Outcome in melanoma is highly dependent on the depth 
of invasion seen in the primary lesion. The predominant 
therapeutic modality in melanoma remains surgical resection 
with adequate margins. However, patients with residual dis-
ease after resection, with lymph node metastases, or with 
distant metastatic spread usually receive adjuvant therapy   
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[6]. Radiation therapy is employed for symptomatic relief of 
brain and visceral metastases that cannot be resected. Ad-
vanced melanoma is highly resistant to most forms of che-
motherapy and response rates to DTIC (dacarbazine) or other 
alkylating agents such as temozolomide (TMZ) [7], car-
mustine and lomustine in combination with spindle poisons 
such as vincristine are seen in approximately 10 to 20% [8-
11]. Biologic treatments are also employed for metastatic 
melanoma, with trials using interferon-alpha and interleukin-
2 generally showing responses in 10 to 20% of patients [12-
14]. However, these treatment strategies have not yet been 
optimized due to a lack of biomarker predictors of response 
to either approach.  
III. MOLECULAR MARKERS OF DYSREGULATED 
GROWTH FACTOR SIGNALING AND THE USE OF 
TYROSINE KINASE INHIBITORS 
  Many of the best characterized somatic mutation and 
epigenetic changes in melanoma involve the receptor tyro-
sine kinase (RTK) signaling pathways, which are particularly 
implicated in sun-exposed (cutaneous) cases [15]. These 
genetic alterations include BRAF, NRAS, KIT and (rarely) 
AKT1/3 point mutation, EGFR and PDGRA genomic ampli-
fication, and epigenetic silencing or mutation of the tumor 
suppressors PTEN and FGFR2 (Fig. 1). 
  BRAF is a serine/threonine kinase that signals down-
stream of RTKs and ras proteins. 30-70% of melanomas 
show BRAF point mutations which alter the autoregulatory 
activation of the kinase, of which the V600E mutation is by 
far the most common. BRAF mutations are most common in 
the nodular and SS types, and rare in AL (5-10% of cases) 
and non-cutaneous melanomas [16-18] (Table 1). BRAF 
mutation correlates with distinct histopathologic features, 
such as intraepidermal melanoma nest formation and a larger 
rounder border of the tumor with surrounding skin, suggest-
ing surrogate markers can be used to select cases for molecu-232    Current Genomics, 2009, Vol. 10, No. 4  Rother and Jones 
lar testing [19]. BRAF mutations also arise more commonly 
in patients with younger age at presentation and lymph node 
metastasis (rather than satellite tumors or visceral metastasis) 
[19]. However, benign nevi show similar or higher rates of 
the V600E BRAF mutation [20, 21], and cell line and trans-
genic mouse models of melanoma do not clearly demonstrate 
the transforming power of this mutation. Germline BRAF 
mutations do not occur in melanoma [22]. 
  NRAS is a GTPase protein which functions to integrate 
signals from multiple RTKs. 10-20% of melanoma have 
point mutations in codon 12, 13 or 61 of NRAS, which are 
almost always mutually exclusive with BRAF mutation [15, 
17, 18, 23]. This is possibly because NRAS-mutated mela-
noma may bypass BRAF and signal through CRAF [24]. 
NRAS mutations are rarely found in benign acquired nevi 
(although seen in congenital nevi) [25], arise later in mela-
noma development, and can produce melanoma in certain 
animal models and are thus are more clearly implicated in 
oncogenesis than BRAF mutations.  
  KIT is a RTK that is essential for normal neural 
crest/melanocyte differentiation. Activating KIT mutations 
are typically seen in mucosal and AL melanoma subtypes (5-
20% of cases) but not in cases arising from chronic sun dam-
age. Point mutations frequently occur in KIT exons 11, 13 
and 17 [26]. The L576P mutation is most common (compris-
ing 50% of mutations). KIT gene amplification also occurs 
[21, 27]. KIT mutations are mutually exclusive with BRAF 
and NRAS, and may identify a subset of melanoma that 
preferentially respond to the KIT inhibitors such as imatinib 
(Gleevec) [28, 29] or sorafenib [30, 31]. There are also regu-
latory changes in KIT expression during melanoma progres-
sion. For example, the highest levels of KIT expression are 
seen at the leading edge of tissue invasion which may indi-
cate a role for dynamic RTK activation in metastasis [26].  
  EGFR is a RTK implicated in normal epithelial and 
melanocyte maturation. It is often overexpressed by gene 
amplification (usually whole gain of chromosome 7) in me-
tastatic melanomas [32], but the prognostic impact of detec-
tion of gene amplification remains unresolved. Rare cases of 
melanoma (often of desmoplastic type) may show activating 
EGFR mutations. The RTKs platelet-derived growth factor 
receptor (PDGR)-alpha and PDGFR-beta are also highly 
expressed in melanocytic lesions [33]. Genomic profiling has 
revealed that AL and mucosal melanomas can have chromo-
somal amplification at chromosome 4q11spanning the 
PDFGRA locus [34, 35] that may contribute to increased 
PDGF signaling [36]. Finally, dominant-negative FGFR2 
mutations have been reported in approximately 10% of 
nodular melanomas [37]. FGFR2 is a RTK that may mediate 
growth arrest in melanoma through interactions with stroma 
so its inactivation may promote tissue invasion.  
  PTEN is a phosphatase that regulates the activation of the 
serine/theronine kinases AKT1/2/3, which are global regula-
tors of cell proliferation. PTEN is regulated as a tumor sup-
pressor with complete PTEN loss (usually accompanied by 
genomic deletion) seen in 20-25% of melanomas (including 
those with BRAF mutation) [38-42], and is highly associated 
with uniform high-level AKT activation [43]. PTEN loss and 
concomitant AKT activation are both usually demonstrated 
by immunohistochemistry, with an anti-phosphoprotein anti-
body against an activation site on AKT (pS473) [40, 43]. 
Rare activation mutations in the AKT1 or AKT3 isoforms 
have been found in sun-exposed melanoma subtypes [44], 
and AKT overexpression may be associated with melanoma 
growth in situ [45, 46]. 
  Variations in the incidence of different RTK pathway 
mutations in different geographic populations are evident 
[47], as well as variations in risk related to polymorphisms in 
other susceptibility loci [48-50]. Since most advanced-stage 
melanomas are resistant to existing adjuvant therapies, 
kinase inhibitors (KIs) have been tried in melanomas that 
demonstrate mutational activation of the kinases above. In 
single case reports or in small series, KIs have shown prom-
ising short-term responses that generally correlate with the 
presence of targetable RTK mutation in the tumor. For ex-
ample, administration of sorafenib (a KI with activity against 
RAF, PDGFR, VEGF, and KIT) along with carboplatin and 
paclitaxel in a phase II trial has led to a partial response rate 
of 26% [51]. Results on the use of imatinib (Gleevec), a KI 
with high activity against KIT and PDGFR, have been dis-
appointing with responses possibly correlated with either 
KIT mutation or high-level KIT protein expression (e.g. 
75% of tumor cells) [52].  
IV. MARKERS OF MELANOMA PROGRESSION 
IDENTIFIED BY GENE EXPRESSION STUDIES 
  Gene expression changes that occur during tumor pro-
gression can be due to chromosomal gains/losses resulting 
from cell cycle alterations (discussed below), activating mu-
tations in pathways that modulate transcription factors (e.g. 
the RTK pathway mutation), or by epigenetic regulation. 
Melanoma at sun-exposed sites may more frequently demon-
strate (UV-induced) genetic mutation whereas melanomas 
arising at non-sun-exposed sites may more frequently utilize 
epigenetic regulation but overlapping patterns are clearly 
seen.  
  This role of epigenetic regulation is clearly highlighted 
by silencing of multiple different tumor suppressor genes 
during melanoma progression. For example, the cell cycle 
regulator p16 is frequently silenced by promoter DNA CpG 
methylation (e.g. 32% of uveal melanoma) [53], as is the 
APC gene which regulates Wnt signaling in 10-20% of cases 
[54], and the kinase regulator RASSF1 in up to 50% of cases 
[55]. The DNA repair gene MGMT (O-6-methylguanine-
DNA-methyltransferase) is silenced in approximately 20% 
of melanoma [56], and its inactivation corresponds with de-
clines in the ability to repair DNA which may promote 
mutagenesis and potentiate the response to DNA-damaging 
chemotherapy [57].  
  Microarray gene expression profiling of primary and 
progressed melanoma and melanoma cell lines have revealed 
many of the coordinated changes in gene expression that 
correlate with clinical stage [36, 56, 58-65]. For example, 
early-stage melanomas often express high levels of the im-
mune modulator CD24 and the transcription factor GATA3, 
whereas progressed melanomas exhibit upregulation of the 
melanoma antigen family A (MAGE) antigens of unknown 
function, and cell cycle regulators such as CDK2 [36]. The 
commonalities arising from these GEP studies of melanoma 
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of transcriptional dysregulation that may prove useful in in-
dividualizing therapy response and in developing novel treat-
ment strategies.  
V. G1-S CHECKPOINT ALTERATIONS IN MELA-
NOMA PROGRESSION 
  Genetic studies [4], genomic profiling [34], and GEP 
have all highlighted the multiple overlapping genetic and 
epigenetic alterations in the proteins regulating the G1-S 
transition in the cell cycle (Fig. 2). Among the 5-10% of 
melanomas with strong familial linkage or inherited germ-
line defects, mutations in p16 (CDKN2A) [4, 5] and CDK4 
[3] are common findings, as is loss of p27 [66, 67] and p16 
[68, 69] expression during progression of sporadic melano-
mas. Indeed, loss of p16 appears to be common to most 
melanoma subtypes including superficial spreading, mucosal 
and nodular cases [38, 68-70]. Secondary genetic changes in 
melanoma also frequently involve the same genes, evidenced 
by the frequent genomic deletions at chr 12q14 spanning the 
CDK4 loci in AL melanoma [67], and chr 17p13 loss at the 
TP53 locus in chronic sun-damage melanomas [34].  
  Multiple abnormalities in the G1-S proteins can occur 
simultaneously in the same melanoma, and occur in tandem 
with RTK alterations outlined above. All of these changes 
would be expected to mediate rapid progression through G1-
S leading to propagation of unrepaired DNA errors. Al-
though these effects are deleterious in terms of cancer pro-
gression, they may predict responsiveness to DNA-damaging 
chemotherapy such as alkylating agents, as discussed below. 
VI. G2-M ALTERATIONS IN MELANOMA PRO-
GRESSION 
  Another major cellular pathway that becomes dysregu-
lated in melanoma progression is the G2-M mitotic transi-
tion. This stage of the cell cycle is regulated by a dynamic 
multi-protein spindle checkpoint complex that assures ade-
quate centrosomal function and accurate chromosomal seg-
regation. Upon activation, the centrosome divides to form 
spindle poles which function to guide chromosomal segrega-
tion. The progression from G2 to M is initiated at the centro-
some by CDK1 and cyclin B if the checkpoint is adequately 
functioning. Spindle function can be negatively regulated by 
p21 and p27 which we have previously discussed as G1-S 
regulators that are frequently dysregulated in melanoma [71]. 
Other regulators of centrosomal/spindle pole function in-
clude the Aurora kinases and RASSF1A [71, 72], both of 
which been shown by us or others to be dysregulated during 
melanoma progression. 
  The RASSF1 gene, located at chr 3p21.3, has several 
different splice isoforms that encode proteins with SARAH, 
ras-association and diacylglycerol-binding domains. Al-
though their functions have not been completely elucidated, 
RASSF1 proteins appear to bind and stabilize a number of 
different kinase complexes involved in apoptosis, prolifera-
tion, and genome maintenance [73, 74]. There are at least 5 
RASSF1 splice isoforms transcribed from different promot-
ers but we find that only the A and C isoforms are expressed 
in melanomas. We and others have shown that the RASSF1A 
splice isoform is differentially silenced by CpG DNA methy-
Table 1.  Incidence of Growth Factor Mutations in Different Melanoma Subtypes 
Site of Melanocytic Lesions 
Incidence of RTK Muta-
tions/Amplification 
Incident of Genetic/Epigenetic  
Cell Cycle Alterations 
References 
Chronic sun-damaged sites 
BRAF: 10% 
NRAS: 20% 
KIT mut/amp: 28% 
CDKN2A/p16 loss: 88% 
[17, 26, 70] 
Nodular sun-exposed sites 
BRAF: 36.3% 
NRAS: 54.5% 
PTEN loss of expression: 7% 
CDKN2A/p16 loss: 78.9% 
p27KIP1 LOH: 38.9%  [18, 37, 40, 67, 69] 
Acral melanoma 
PDGFRA amp: 18% 
KIT mut/amp: 36% 
FGFR2 mutation: 4% 
CDK4 amp: 23% 
CCND1 (cyclin D1) amp: 23% 
PDGFRA amp: 18% 
[26, 34, 37] 
Mucosal melanoma 
KIT mut/amp: 53.3% 
FGFR2 mutation: 6% 
CDKN2A/p16 LOH: 33% 
[16, 26, 37, 68] 
Uveal melanoma 
PTEN LOH: 39.5% 
PTEN loss of expression: 16% 
CDKN2A/p16 methylation: 32% 
[39, 53] 
Congenital nevi  NRAS: 81.3%    [25] 
Sporadic nevi  BRAF: 20%    [20] 
Inherited melanoma syndromes 
  CDKN2A/p16 mutation: 70% 
CDK4 amp: (infrequent) 
[1-4, 58] 
Abbreviations: mut: point mutation; amp: genomic amplification; LOH: loss of heterozygosity (genomic deletion). 234    Current Genomics, 2009, Vol. 10, No. 4  Rother and Jones 
lation during melanoma progression in 20-50% of primary 
tumors and in established melanoma cells lines [55, 75]. This 
silencing results in an imbalance between the amount of 
RASSF1A and the ubiquitously expressed RASSF1C iso-
forms (Fig. 3).  
  The best characterized function for RASSF1A is in com-
plex stabilization of the mitotic spindle during one phase of 
the G2-S transition [72, 76]. But we have noted that differ-
ences in the levels of RASSF1A (due to varying levels of 
CpG methylation of its promoter) in melanoma cells leads to 
altered cellular localization patterns and likely different func-
tions. For example, melanomas with very low RASSF1A 
expression show discrete nuclear positivity in only rare cy-
cling tumor cells, whereas tumors with high RASSF1A ex-
pression show preferential cytoplasmic, membrane and nu-
clear localization patterns depending on tumor type (Fig. 4A 
and not shown).  
  During cell division in melanoma, RASSF1A shifts from 
its predominant localization with the microtubles in the cy-
toplasm to discrete locations within the mitotic spindle (Fig. 
4B). These shifts are transient and dependent on the recruit-
ment of other spindle components such as Aurora kinases 
(Fig. 4C). Melanoma cells treated with spindle toxins such 
as paclitaxel or vinblastine show trapping of RASSF1A in 
the altered mitotic spindle. Tumor cells with diminished 
RASSF1A have a greater tendency to develop chromosomal 
aberrations [77, 78].  
VII. IDENTIFYING WHICH MELANOMAS MIGHT 
BENEFIT FROM CHEMOTHERAPY  
  Although profiling of growth factor pathway alterations 
may be useful in selecting patients for KI therapy, NRAS 
and BRAF mutation status have shown no or limited correla-
tion with response to chemotherapy or immunotherapy. 
There is as yet too limited data on the correlative responses 
of melanomas with FGFR2, PTEN/AKT or KIT mutations. 
Therefore most studies have focused on identifying predic-
tors of chemotherapeutic response.  
  The drugs typically used to treat melanoma include car-
boplatin and cisplatin, alkylating agents, and mitotic spindle 
poisons such as vinblastine and paclitaxel. Resistance to cis-
platin in melanoma may be related to sequestration of the 
Table 2.  Genes Involved in Melanoma Progression Identified by Gene Expression Profiling 
Gene Function  Fold-Change  Comparison  Group  References 
Upregulated 
 
BIRC5 
Component of chromosome passenger complex that 
ensures chromosome alignment/segregation 
3-5X 
primary  metastasis 
primary  metastasis 
[36, 64] 
BUB 
Mitotic kinase that functions in spindle  
checkpoint function 
4-11X 
primary  metastasis 
nevi  melanoma 
[36, 59] 
CDK2  Kinase that regulates the G1-S transition  3-9X 
primary  metastasis 
nevi  melanoma 
[36]  
[65] 
CHEK1 
Mitotic kinase that phosphorylates  
cdc25 at G2-M transition 
nr 
nevi  melanoma 
blood of metastatic cases 
[60, 62] 
CCNA2 
(cyclin A) 
Binds and activates CDC2 and CDK2 at  
the G1-S and G2-M transition 
nr
  nevi  melanoma
  [60, 63] 
MAGEA1 
Mediator of transformation through extracellu-
lar/adhesion signaling 
25X 
primary  metastasis  
primary  metastasis 
[36, 61] 
MAGEA2 As  above  31X 
primary  metastasis 
primary  metastasis 
[36, 61] 
Downregulated   
MAP4 
Microtubule binding protein stabilizing the cyclin 
B/CDC2 kinase mitotic complex 
20X nevi   melanoma 
[36] 
 
CDKN2A/p16 
Cyclin-dependent kinase inhibitor  
that regulates G1-S transition 
nr 
primary  metastasis 
primary  metastasis 
[58]  
[83] 
CDKN1B/p27 
Inhibitor of cyclin E-CDK2 and cyclin  
D-CDK4 complexes at G1-S transition 
nr 
primary  metastasis 
primary  metastasis 
[67] 
[58] 
SFN  Inhibitor of p53 function at G2-M transition  24X 
primary  metastasis 
primary  metastasis 
[36, 61] 
FGFR3  RTK stromal signals/differentiation  8X primary   metastasis  [36, 61]
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Fig. (1). Receptor tyrosine kinase (RTK) pathway dysregulation in melanoma pathogenesis. Genetic alterations seen in different subsets 
of melanoma include point mutation (*) of the RTK KIT, genomic amplification () of EGFR and PDGRFA, point mutation of NRAS and 
BRAF, complete loss of PTEN expression (), and rarely point mutation of AKT1 and AKT3 (*).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Cell cycle dysregulation in melanoma progression. Complex patterns of transcriptional and epigenetic regulation of the cyclin-
dependent kinases (CDKs), CDK inhibitors and the p53 axis have been demonstrated in microarray genomic and expression studies of mela-
noma progression. These include downregulation () of inhibitors of CDK by DNA methylation silencing, deletion and transcriptional net-
works, and genomic amplification and microRNA regulation of CDKs and cyclins. 236    Current Genomics, 2009, Vol. 10, No. 4  Rother and Jones 
 
 
 
 
 
 
 
 
 
Fig. (3). Variations in RASSF1 isoforms in melanoma cell lines. A. The MeWo line, established from a lymph node melanoma metastasis, 
shows higher RASS1A levels compared to RASSF1C. WM-2664, established from a cutaneous melanoma, shows higher RASSFC than 
RASSF1A. Lines A375 and C8161 lack RASSF1A expression due to promoter methylation silencing. Studies were performed by TaqMan 
reverse transcription (RQ)-PCR using a RASSF1A-specific primer-probe set (Applied Biosystems, Foster City, CA) with normalization to 
GUSB transcript levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Variable RASSF1A expression in melanoma. (A) High level RASSF1A expression in the cytoplasm of a melanoma metastatic to 
lymph nodes is contrasted with near absence of expression in another progressed melanoma. White arrows highlight the nuclear localization 
of RASSF1A seen in cycling cells. Immunohistochemical staining was performed on formalin-fixed paraffin-embedded tumor sections using 
a mouse monoclonal antibody (eB114-10H1. eBioscience, San Diego, CA) and the ABC avidin-biotin detection method. Activated endothe-
lium within each tissue serves as a positive control. (B) RASSF1A in non-dividing cells is present in the cytoplasm in association with the 
actin-tubulin cytoskeleton. During the later stages of mitosis, RASSF1A transiently colocalizes with tubulin and other spindle components at 
the spindle poles. Use of mitotic spindle inhibitor (paclitaxel) results in trapping of RASSF1A in stalled mitotic spindle complexes. Confocal 
microscopy performed with RASSF1A polyclonal antisera (N-12, Santa Cruz Biotechnology, Santa Cruz, CA), and a beta-tubulin mouse 
monoclonal antibody (clone DM1A, Sigma). (C) In melanoma cell lines, RASSF1A and Aurora kinases colocalize at the mitotic spindle in a 
subset of cells. Confocal microscopy was performed using a pan-phospho-Aurora antisera (Thr288A/Thr232B/ Thr198C, Cell Signaling 
Technology, Beverly, MA) and a RASSF1A mouse monoclonal antibody (eB114-10H1, eBioscience). Melanoma Progression  Current Genomics, 2009, Vol. 10, No. 4    237 
 
drug in melanosomes [79, 80], and resistance to alkylating 
agents may be mediated by expression of MGMT, which 
opposes their action [81]. However, since therapeutic activity 
of alkylating agents and DNA-damaging agents require tu-
mor cell division, melanomas with a higher proliferative rate 
or those with genetic alterations in checkpoint function may 
be more likely to respond [82].  
  Since the spindle poisons (paclitaxel, vincristine, or vin-
blastine) are typically components of most multi-agent che-
motherapy regimens, identification of predictors of response 
to this class of agents would be clinically useful. These drugs 
block cell division by interfering with microtubule function 
essential for chromosomal segregation and cytokinesis. 
Since abnormalities in mitotic regulators such as RASSF1A 
and Aurora kinases are common in melanoma they represent 
obvious candidate biomarkers. Indeed, in advanced stage 
melanoma, RASSF1A appears to correlate to some degree 
with response to chemotherapy. As a result, profiling of the 
activation state or the degree of mitotic spindle dysfunction 
using these markers shows promise in identifying those pa-
tients who would benefit most from spindle toxins. Addi-
tionally, strategies to restore loss of expression of spindle 
checkpoint proteins such as RASSF1A by use of demethylat-
ing agents (or more targeted methods) may be useful in re-
versing genetic instability associated with tumor progression. 
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